C. Barton

发表

Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome

Kristina M. Ilieva, J. Spicer, S. Till, 2020, Cells.

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Kristina M. Ilieva, S. Tsoka, D. Dombrowicz, 2017, Cancer research.

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

F. Shepherd, U. Gatzemeier, A. Ardizzoni, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

J. Jassem, A. Wardley, X. Pivot, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin-based chemotherapy for bladder cancer.

C. Barton, J. Waxman, 1993, Cancer treatment reviews.

Effects of chemotherapy on fertility.

C. Barton, J. Waxman, 1990, Blood reviews.

Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti‐tumor IgE therapeutic candidate

Kristina M. Ilieva, S. Pinder, J. Spicer, 2020, Allergy.

Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.

T. Hickish, S. Johnston, I. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT145: A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma

John Anderson, G. Barone, K. Straathof, 2018, Clinical Trials.

Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients.

I. Ferrier, P. Groundwater, M. Tisdale, 1990, British Journal of Cancer.

Bladder cancer: inter-relationships between chemotherapy and radiotherapy.

K. Sikora, P. Abel, R. Biruls, 1992, British journal of urology.

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

R. Gelber, M. Piccart, J. Baselga, 2021, British Journal of Cancer.

Beta-glucan contamination of pharmaceutical products: How much should we accept?

J. Spicer, D. Josephs, S. Karagiannis, 2016, Cancer Immunology, Immunotherapy.

A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.

M. Piccart, D. Richel, J. Bonneterre, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

An immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE

Kristina M. Ilieva, S. Tsoka, D. Dombrowicz, 2018, Allergy.

Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

K. McHugh, I. Dragoni, A. Akarca, 2020, Science Translational Medicine.

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

J. Baselga, V. Harvey, S. Morales, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

J. Baselga, M. Climent, W. Eiermann, 2010, The Lancet.

Development of downstream processing to minimize beta‐glucan impurities in GMP‐manufactured therapeutic antibodies

J. Spicer, D. Josephs, S. Karagiannis, 2016, Biotechnology progress.

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.

T. Suter, C. Barton, N. Cook-Bruns, 2004, Breast.

Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.

A. Dalgleish, C. Barton, J. Waxman, 1992, European journal of cancer.

A phase II study of ifosfamide in endometrial cancer

G. Blackledge, C. Barton, C. Meanwell, 2004, Cancer Chemotherapy and Pharmacology.

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.

J. Baselga, B. Leyland-Jones, M. Marty, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)

J. Baselga, B. Leyland-Jones, U. Gatzemeier, 2004 .

Three-monthly GnRH agonist (buserelin) for prostatic cancer.

P. Abel, P. Keane, G. Williams, 1990, British journal of urology.

Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.

R. Coombes, J. Bliss, R. Stein, 1992, European journal of cancer.

Reply to S.M. Ali et al

J. Baselga, B. Leyland-Jones, M. Marty, 2009 .

Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.

S. Halford, G. Acton, H. Wong, 2016, European journal of cancer.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

A. Harris, S. Halford, R. Eastell, 2018, British Journal of Cancer.

inhibitor AZD 0424

A. Harris, S. Halford, R. Eastell, 2018 .

Alteration ofserumandurinary lipolytic activity withweight loss in cachectic cancerpatients

I. Ferrier, P. Groundwater, M. Tisdale, 1990 .

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Kristina M. Ilieva, S. Canevari, U. Banerji, 2023, Nature communications.

Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer

Kristina M. Ilieva, S. Pinder, U. Banerji, 2020, Tumor Biology.

Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).

R. Gelber, J. Baselga, G. Viale, 2018 .